MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
61.99
+2.47
+4.15%
After Hours: 61.75 -0.24 -0.39% 19:59 02/06 EST
OPEN
60.00
PREV CLOSE
59.52
HIGH
62.05
LOW
59.77
VOLUME
17.12M
TURNOVER
--
52 WEEK HIGH
62.05
52 WEEK LOW
41.88
MARKET CAP
126.20B
P/E (TTM)
17.92
1D
5D
1M
3M
1Y
5Y
1D
A Look At Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Strong 2026 Guidance
Simply Wall St · 18h ago
Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
Seeking Alpha · 1d ago
Bristol Myers Squibb (BMY) Returns To US$7.1b Trailing Profit Challenging Bearish Narratives
Simply Wall St · 1d ago
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
Seeking Alpha · 2d ago
Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
Dow Jones · 2d ago
Bristol-Myers Squibb Price Target Raised to $64.00/Share From $60.00 by Citigroup
Dow Jones · 2d ago
Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $64
Benzinga · 2d ago
Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 2d ago
More
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.